Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note
Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
First Phase II results show decrease in UV-induced skin damage
Read More
CLINUVEL Communiqué VI
Melbourne, Australia, 23 December 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notification of cessation of securities
Melbourne, Australia, 21 December 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Jefferies London Healthcare Conference
CLINUVEL's Chief Executive Officer, Dr Philippe Wolgen, presents to the Jefferies Healthcare...
Read More
CLINUVEL Communiqué V
News Communiqué V discusses CLINUVEL's strong financial results in the face of...
Read More
Appendix 3Y - Change of Director’s Interest Notice
Melbourne, Australia, 07 November 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More